In a significant advancement for diabetes care, Health Canada has approved the first generic version of semaglutide, a medication commonly known through its brand names like Ozempic. This decision marks Canada as the first country within the G7 to introduce this affordable alternative. Manufactured by Dr. Reddy’s Laboratories in India, the generic medication, marketed as “Obeda” in its home country, is designed for weekly injection to aid adults managing Type 2 diabetes.
A Step Towards Affordability in Diabetes Care
Health Canada’s recent approval is not just a win for patients but a pivotal moment in the broader healthcare landscape. The agency announced that it is currently reviewing eight additional applications for generic semaglutide, suggesting a potential influx of alternatives that could further reduce costs for patients across the country.
Dr. Hertzel Gertstein, a professor at McMaster University and a diabetes specialist, emphasised the rigorous evaluation process that generic drugs must undergo before gaining approval. He reassured patients, stating, “When Health Canada approves a generic version of a drug, they go through a very rigorous process and ensure that the drug is as chemically similar to the original as possible. The fact that they’ve approved it should reassure most people that using these generics will have a very similar, if not identical, effect as the original.”
Cost Implications: A Game Changer for Many
The financial burden of diabetes medications can be daunting. According to Felix, a Canadian integrated healthcare platform, the average monthly cost for Ozempic injections ranges from £200 to £450, varying by province. Other medications, such as Mounjaro and Wegovy, can cost even more, with monthly prices soaring up to £550 and an annual cost of £5,066, respectively.
The introduction of the first generic version is particularly promising, as initial pricing for generics typically falls between 75% to 85% less than their branded counterparts, according to the pan-Canadian Pharmaceutical Alliance. As more generics enter the market, these prices are expected to decrease further, potentially dropping to around 35% of the original cost when three or more options are available.
Dr. Dana Small, a neurology and neurosurgery expert at McGill University, highlighted the potential for drastic reductions in cost, stating, “The numbers I’ve heard are anywhere from £40 to £80. That’s a major decrease in cost.” She added that these savings could also benefit research initiatives in various fields.
Navigating Provincial Drug Plans
While the federal approval from Health Canada is a pivotal step, the path to inclusion in provincial drug benefit programmes remains complex. Dr. Gertstein noted that the acceptance of generic GLP-1 drugs, such as semaglutide, into public drug plans can vary significantly from one province to another. For instance, Ontario may approve reimbursement under the Ontario Drug Benefit programme while other provinces, such as Manitoba, may not.
Dr. Small pointed out the economic rationale behind including generic drugs in insurance plans. “I think it will overall benefit the health system by reducing costs related to obesity treatment and cardiovascular diseases,” she explained. “The cost-benefit analysis will show that there is a net gain due to the prevention of chronic diseases and the associated hospital care costs.”
However, both experts cautioned that while the drugs can lead to significant weight loss and improved glucose control, patients should consider the long-term commitment required. “Once you start taking the drugs, you can lose a lot of weight and improve glucose control. But if you stop, everything goes back to how it was,” Dr. Small warned. “It’s a long-term commitment.”
Why it Matters
The approval of the first generic semaglutide in Canada is a landmark achievement that promises to enhance patient access to essential diabetes medications, potentially transforming treatment paradigms across the nation. As generics continue to emerge, they not only hold the promise of affordability but also the opportunity for improved health outcomes in a population that grapples with rising rates of Type 2 diabetes. By prioritising accessibility in healthcare, Canada is setting an example for the G7 and beyond, championing a model that could lead to more equitable health solutions for all.
